kristoff@GENBANK.BIO.NET (Dave Kristofferson) (03/23/91)
$$XID NIHGUIDE 19910322 V20N12 P1O1 ************************************
X-comment: RFAs described: HL-91-04-B
NIH GUIDE - Vol. 20, No. 12, March 22, 1991
$$INDEX BEGIN **********************************************************
NOTICES
$$INDEX N1 *************************************************************
REVIEW PROCEDURES FOR NEW COMPETITIVE PROGRAM PROJECT GRANT
APPLICATIONS SUBMITTED JUNE 1, 1991 AND OCTOBER 1, 1991
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, BLOOD
$$INDEX N2 *************************************************************
NIH REGIONAL SEMINAR IN GRANTS ADMINISTRATION
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
NOTICES OF AVAILABILITY (RFPs AND RFAs)
$$INDEX R1 *************************************************************
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN FIRST SEIZURE PATIENTS (RFI)
National Institute of Neurological Disorders and Stroke
Index: NEUROLOGICAL DISORDERS, STROKE
$$INDEX R2 06/24/91 ****************************************************
FACILITIES CONSTRUCTION PROJECTS TO SUPPORT CENTERS FOR SUBSTANCE
ABUSE RESEARCH (RFA DA-91-06)
National Institute on Drug Abuse
Index: DRUG ABUSE
$$INDEX R3 07/15/91 ****************************************************
GENE THERAPY STRATEGIES FOR TREATMENT OF COOLEY'S ANEMIA (RFA
HL-91-04-B)
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, BLOOD
ONGOING PROGRAM ANNOUNCEMENTS
$$INDEX P1 *************************************************************
TRANSGENIC, CHIMERIC, AND IN VITRO MODELS OF KIDNEY DISEASES (PA-91-35)
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES
$$INDEX P2 *************************************************************
SMALL GRANT PROGRAM (PA-91-36)
National Institute of Dental Research
Index: DENTAL RESEARCH
ERRATA
$$INDEX E1 06/13/91 ****************************************************
CORRECTION: SUPERFUND HAZARDOUS SUBSTANCES BASIC RESEARCH PROGRAM
(RFA ES-91-02)
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES
$$INDEX END ************************************************************
NOTICES
$$N1 BEGIN *************************************************************
REVIEW PROCEDURES FOR NEW COMPETITIVE PROGRAM PROJECT GRANT
APPLICATIONS SUBMITTED JUNE 1, 1991 AND OCTOBER 1, 1991
P.T. 34; K.W. 1014002, 1014006
National Heart, Lung, and Blood Institute
Effective with the receipt of applications due June 1, 1991 and
October 1, 1991, new and amended new competitive program project
grant applications assigned to the National Heart, Lung, and Blood
Institute (NHLBI) will be reviewed on a
schedule longer than has been the custom in the past. This is
necessary in order to carry out the usual NHLBI peer review
process for program project grant applications at a time when the
number of applications has greatly increased. These applications
will be reviewed by the NHLBI review branch in as timely a manner
as is practicable.
The submission of many program project grant applications in
excess of the usual workload has already necessitated the delay in
review of many applications and has placed a significant burden on
review staff, reviewers, and scheduling. The increased percentage
of amended applications has contributed to this problem.
The nature of the program project grant has evolved greatly since
its inception in the early 1960s. Because of the recent
circumstances, the NHLBI is taking the opportunity in the next
9 months to examine the program project grant mechanism. To this
end, two NHLBI staff committees are being established to revise
program project guidelines and review procedures. The National
Heart, Lung, and Blood Advisory Council and extramural scientists
will be part of this process. It is currently expected that new
program guidelines and review procedures will be presented to the
Council in October 1991 with implementation for the February 1,
1992 deadline.
For these reasons, new (Type 1 and amended Type 1) program project
grant applications will experience delays in the review cycle.
Competing renewal and amended renewal applications will be
reviewed under previous schedules in order to avoid gaps in
funding and to lessen any problems associated with phasing out of
ongoing research efforts and to maintain, where possible,
personnel and institutional commitments of currently funded
programs.
Questions about this announcement should be directed to:
Ronald G. Geller, Ph.D.
Director, Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 7A/17
Bethesda, MD 20892
Telephone: (301) 496-7416
$$N1 END ***************************************************************
$$N2 BEGIN *************************************************************
NIH REGIONAL SEMINAR IN GRANTS ADMINISTRATION
P.T. 42; K.W. 1014006
National Institutes of Health
The Grants Policy Office of the National Institutes of Health (NIH)
is sponsoring a two-day seminar on program funding and grants
administration. The seminar covers topics of interest to both
academic researchers and grants administrators and will be held
on May 20-21, 1991, at Indiana University School of Medicine,
Indianapolis.
The conference is targeted for an audience of researchers and
research administrators at institutions in the Midwest region
of the country. Those interested from other states are also
invited. Investigators and staff from small and minority
colleges, for-profit research organizations, hospitals,
universities, and research institutes are encouraged to attend.
Discussions of current issues that affect NIH funding and grants
administration are included to give conference participants a
comprehensive, up-to-date view of NIH-sponsored research. The
first day of the conference focuses on current areas of interest
to the research programs of the various awarding components that
comprise the NIH. Preparation of an NIH application/proposal and
the NIH review process are included as agenda topics. In
addition, a panel of Principal Investigators from Indiana
University School of Medicine will give their perspective and
advice on writing successful applications/proposals.
The program for the second day covers topics associated with pre-
award and post-award administration of NIH grants and contracts.
Policy and procedural issues affecting NIH grants administration
form the basis of the program. General discussions on current
issues and the changes they precipitate are integrated with more
specific discussions regarding special career development
programs, conflict of interest guidelines, and electronic grant
application development.
Mr. Geoffrey Grant, Grants Policy Officer in the Office of
Extramural Research at NIH and program and grants management
staff from several NIH institutes and centers as well as
representatives from the Division of Research Grants are featured
speakers. Time will be available each day for conference
participants to meet informally with the NIH representatives to
discuss topics of special interest.
Conference agenda and fee information are available.
For more information, contact Ms. Jan Walther, Indiana
University School of Medicine, at (317) 274-7127.
$$N2 END ***************************************************************
NOTICES OF AVAILABILITY (RFPs AND RFAs)
$$R1 BEGIN NIH-NINDS-91-001 ********************************************
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN FIRST SEIZURE
PATIENTS
REQUEST FOR INFORMATION SYNOPSIS NO.: NIH-NINDS-91-001
P.T. 34; K.W. 0715060, 0755015, 0745005
National Institute of Neurological Disorders and Stroke
Whether early treatment of non-febrile seizures can alter
the likelihood of the development of chronic epilepsy is a
question yet unresolved. The National Institute of
Neurological Disorders and Stroke (NINDS), NIH, is
interested in identifying organizations that are potential
sources of non-adult patients with first non-febrile
seizures for a randomized, double-blind,
placebo-controlled trial of the treatment of first
seizures. The NINDS is interested in comparing two randomly
assigned groups of patients, those assigned to receive an
anti-epileptic drug (AED) after the first seizure and those
assigned to receive a placebo. The primary comparison will
be the proportion of patients with recurrent seizures in
each group after treatment and follow-up (up to two years).
The NINDS is seeking to determine whether appropriate
populations exist for such a clinical trial.
Specifically, information is requested to assess
availability of the following:
1. The number of patients diagnosed with first seizure
each month in your institution for the past three (3)
years, according to decades of age. There must be documented
availability of approximately 150 non-adult (6 months to 19
years of age) patients in the first year of enrollment. Patients
must be without prior non-febrile seizures, with a
maximum of one week of AED treatment for the presenting
seizure, and who could be entered into a trial within one week
of their first seizure.
Immediacy of screening to permit
randomization prior to recurrent seizure is a high priority
criterion.
2. The current practice in your institution for
treating patients with first seizures, including first AED
choices, methods for identifying a seizure, a non-febrile
seizure, and a first non-febrile seizure.
3. The clinical staff and routine resources available
to diagnose, treat, and follow this type of patients.
Provide names and professional qualifications and specific
experience of clinical personnel who have been involved
with trials of a similar nature.
4. Summary of baseline data currently collected on
first seizure patients, summary of follow-up data currently
and routinely collected, e.g., current frequency of CT
scans and/or EEG's. Median duration of patient contacts
over the past three (3) years.
5. Identification of the support staff and experience
in data entry and data management for clinical trials.
Responses to this request are not mandatory and are
solicited on a voluntary basis. A statement of
capabilities and qualifications should not exceed 15 typed
pages. This announcement does not commit the Government to
make an award nor to pay for the preparation of any
information submitted. This is not a Request for
Proposals. Acknowledgement of receipt of responses will
not be made, nor will respondents be notified of the
Government's evaluation of the information received.
Responses should be identified with NIH-NINDS RFI Synopsis
No. 91-001, and are due 30 days after the publication date
of this synopsis. Three (3) copies of your response must
be delivered/mailed to:
Mr. Kirkland L. Davis
Contracting Officer
National Institute of Neurological Disorders and Stroke
NIH
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, MD 20892
$$R1 END ***************************************************************
$$R2 BEGIN DA-91-06 ****************************************************
FACILITIES CONSTRUCTION PROJECTS TO SUPPORT CENTERS FOR
SUBSTANCE ABUSE RESEARCH
RFA AVAILABLE: DA-91-06
P.T. 03; K.W. 0404003, 0404009, 0785035
National Institute on Drug Abuse
Letter of Intent Receipt Date: May 15, 1991
Application Receipt Date: June 24, 1991
Purpose: The Fiscal Year 1991 HHS/Labor appropriation bill
(PL 101-517) authorized the Alcohol, Drug Abuse, and Mental Health
Administration (ADAMHA) to award competitive grants for
the construction and renovation of research facilities. This
authorization was based on Congress' belief that there is a need
for substance abuse research centers that combine substance
abuse treatment programs in the same physical location with
inpatient and outpatient clinical research programs and related
basic science laboratories.
Support may be requested for the costs of constructing or
renovating non-Federal facilities to meet the needs of an
integrated research facility, to include clinical and basic
research activities on drug and/or alcohol abuse and associated
substance abuse treatment activities.
The overall objective of this Request for Applications (RFA) is
the creation of facilities
that will provide an enhanced environment for the development of
basic and clinical research findings on substance abuse and for
the rapid transfer of research findings to the clinical care of
patients suffering from substance abuse. In addition, the
Centers will facilitate improved diagnostic capabilities by
treatment providers, physicians, investigators, clinicians and
rotating interns, as well as stimulate interest/commitment in
substance abuse research.
Award Mechanism: The award mechanism will be the construction
grant award (C06).
Eligibility: Any domestic, non-Federal, profit or nonprofit
institution, or public organization, or association is eligible
to apply. However, to assure that the completed facility will be
used in accord with the objectives and scope of this RFA,
applicants must be conducting basic and/or clinical research on
substance abuse and be engaged in the treatment of substance
abuse. Applicants may include universities, colleges, hospitals,
public agencies, research institutions, and similar
organizations, profit or nonprofit. ADAMHA staff will verify
application and award eligibility. Applications judged to be
ineligible will be returned to the applicant.
Funding: This one-time solicitation, based on Fiscal Year 1991
appropriations, will make available approximately $4,900,000 to
cover allowable costs of approximately 2 construction/renovation
projects. Allowable costs under Federal regulations may be less
than total construction costs to the institution. ADAMHA
encourages but does not require the applicant to arrange
additional funding from non-Federal sources for at least 25 percent of
the total costs. In any case, prior to the grant award, the
applicant must provide an assurance that sufficient funds have
been secured from non-federal sources to meet any projected costs
in excess of the award amount. All awards under this RFA will be
one-time awards that will cover the federal participation for
the entire construction/renovation project. No continuation
costs and no indirect costs will be awarded.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES. For projects involving clinical
research, ADAMHA requires applicants to give special attention to
the inclusion of women and minorities in study groups. If women
and minorities are not included in the populations for
clinical studies, a special justification for this exclusion must
be provided. Applications without this justification will not be
accepted for review.
Letter of Intent: Prospective applicants are asked to submit by
May 15, 1991, a short letter of intent to the individual noted
below. The RFA describes procedures for submitting this
letter.
Application Process: Applicants must use Standard Form 424,
"Application for Federal Assistance." For additional
information, a copy of the RFA, the Standard Form 424
application, and additional special instructions and guidelines,
please contact:
John J. Boren, Ph.D.
Chief, Clinical and Behavioral Pharmacology Branch
Division of Clinical Research
National Institute on Drug Abuse
5600 Fishers Lane, Room 1OA-46
Rockville, MD 20857
Telephone: (301) 443-1263
For fiscal and administrative matters, contact:
Ms. Shirley McKinney
Grants Management Officer
National Institute of Drug Abuse
5600 Fishers Lane, Room 8A-54
Rockville, MD 20879
Telephone: (301) 443-6021
PRE-APPLICATION INSTRUCTIONS: Intergovernmental Review-Executive
Order 12372 (rev. 3/l/91)
The intergovernmental review requirements of Executive Order
12372, as implemented through DHHS regulations at 45 CFR Part
100, are applicable to this program. E.O. 12372 sets up a system
for State and local government review of proposed Federal
assistance applications. Applicants (other than Federally
recognized Indian tribal governments) should contact the State
Single Point of Contact (SPOC) as early as possible to alert them to
the prospective applications and to receive any necessary
instructions on the State process. A current listing of SPOCs is
included in the application kit.
$$R2 END ***************************************************************
$$R3 BEGIN HL-91-04-B FULL-TEXT ****************************************
GENE THERAPY STRATEGIES FOR TREATMENT OF COOLEY'S ANEMIA
RFA AVAILABLE: HL-91-04-B
P.T. 34; K.W. 0745032, 0715032
National Heart, Lung, and Blood Institute
Application Receipt Date: July 15, 1991
The Cellular Hematology Branch of the Division of Blood
Diseases and Resources, National Heart, Lung, and
Blood Institute, announces the availability of a
Request for Applications (RFA) on the above subject.
Awards will be made to foreign institutions only for
research of very unusual merit, need, and promise.
This special program will support research on the
development of techniques and strategies for the high-
efficiency transfer and long-term expression of normal human
beta-globin genes into hematopoietic stem cells in culture
and in animals as a first step in the development of a
protocol for treating patients with Cooley's anemia.
The support mechanism for this FIVE-year program will be the
traditional individual research grant (R01). Although
approximately $1,000,000 (for direct plus indirect costs) for
this program is included in the financial plans for fiscal
year 1992, award of grants pursuant to this Request for
Applications (RFA) is contingent
upon receipt of funds for this purpose. The specific number
of awards to be funded depends on the merit and scope of the
applications received and the availability of funds.
It is anticipated that approximately five awards will be made.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES
For projects involving clinical research, NIH requires applicants
to give special attention to the inclusion of women and
minorities in study populations. If women or minorities are not
included in the study populations for clinical studies, a
specific justification for this exclusion must be provided.
Applications without such documentation will not be accepted for
review.
Requests for copies of the RFA may be addressed to:
Helena O. Mishoe, Ph.D.
Health Scientist Administrator
Cellular Hematology Branch
National Heart, Lung, and Blood Institute
Federal Building, Room 5A12
Bethesda, MD 20892
Telephone: (301) 496-5911
FAX: (301) 496-9940
For fiscal and administrative matters, contact:
Ms. Jane Davis
Grants Management
National Heart, Lung, and Blood Institute
Westwood Building, Room 4A15
5333 Westbard Avenue
Bethesda, MD 20892
Telephone: (301) 496-7257
$$R3 END ***************************************************************
ONGOING PROGRAM ANNOUNCEMENTS
$$P1 BEGIN *************************************************************
TRANSGENIC, CHIMERIC, AND IN VITRO MODELS OF KIDNEY DISEASES
PA: PA-91-35
P.T. 34; K.W. 0755020, 0785095, 0785220, 1002004, 1002002, 0780015
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates: June 1, October 1, and February 1
The Division of Kidney, Urologic and Hematologic Diseases
(DKUHD) of the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) announces a continuing interest
in receiving research project applications on the above
subject.
BACKGROUND
The need for this initiative was recognized, in part, as a
result of a 40th Anniversary Symposium held at NIH in March
1990, organized and sponsored by the DKUHD, titled "Gene
Regulation and Cellular Signaling in the Kidney and
Urothelium." There have been marked successes in
identifying genetic defects involved in diseases of other
organs and systems, such as the blood. The power of
molecular and cellular techniques in determining the
structure of genes and in obtaining information about their
regulation has been amply demonstrated in these other
systems. As summarized in the symposium, recent
investigations of the kidney and urothelial system,
particularly with growth factors and their signal
transduction systems and with transporter proteins and their
genes, indicate that the diseases of the kidney, such as
polycystic kidney disease and Alport Syndrome, also can be
attacked productively through molecular and cellular
approaches.
There is a need for expansion of model systems for use in
studying kidney and urological diseases to complement the
rapidly expanding arsenal of molecular and cellular
techniques. Some valuable approaches that have been
identified for modeling other human diseases are beginning
to be applied to kidney problems, e.g., transgenic mice have
been made that carry various growth factor genes, chimeric
mouse kidneys derived from two species have been constructed
in vivo at embryonic stages, and in vitro culture techniques
are being used that involve co-culture of two or more
kidney-derived cell lines. Development of additional
transgenic animals that mimic human kidney disorders would
be valuable, as would other in vivo and in vitro approaches
along the lines briefly summarized here.
The kidney programs of this division have a long and well-
documented history of support for investigations into the
physiology and cell biology of the kidney (e.g., transport
systems) and kidney morphogenesis and growth, all of which
support this natural progression into the molecular arena
and the need for complementary model systems as described
above.
RESEARCH GOALS AND SCOPE
The purpose of this initiative is to stimulate research into
the molecular and cellular basis of kidney diseases, with an
emphasis on approaches using transgenic animals, chimeric
kidneys, and in vitro models. To that end, the following
are some of the objectives of this solicitation that are
being encouraged:
o Development of transgenic mouse lines carrying various
growth factor genes. Transgenic mice carrying numbers of
copies of the human growth hormone gene have been created
and examined with respect to kidney size and growth
parameters. Development of transgenics expressing genes for
other growth factors that affect kidney development and
regeneration is encouraged.
o Development of chimeric kidneys in vivo, beginning at the
embryonic stages as has been done between different strains
of mice, might be extended to other rodent species that
serve as models for diseases such as polycystic kidney
disease (PKD). The role of different cell types in normal
development and in the disease process can be explored by
using cell types with different genetic markers from
different strains or species.
o Development of new kidney-derived cell lines and co-
culture of cell lines to further define cellular
interactions involved in disease processes and in kidney
morphogenesis and regeneration.
o Development of renal epithelial cell lines stably
transfected with inducible genes involved in (a) signal
transduction, (b) growth and development, and (c) ion
channel regulation.
o Development of in vitro models to facilitate studies of
kidney cell biology and/or interactions between the kidney
and the immune system. Examples are models for studying (a)
polar targeting of membrane proteins, (b) vesicular
trafficking in physiological and pathophysiological
processes, and/or (c) kidney antigen processing and
trafficking in cells of the immune system, i.e., in
lymphocytes and macrophages.
The above are examples only and should not be viewed as all
inclusive.
MECHANISMS OF SUPPORT
Support for this program will be through the grant-in-aid
and will be governed by the current policies of grant
programs of the National Institutes of Health. New
applications may be submitted for the traditional,
investigator-initiated research project grant (R01) and
First Independent Research Support and Transition (FIRST)
Awards (R29). Under these mechanisms, the applicants will
plan, direct, and conduct the research programs. The
project periods during which the research will be conducted
should adequately reflect the time required to accomplish
the stated goals and be consistent with the policy for grant
support. Support will be provided for up to 5 years
(renewable for subsequent periods) subject to the
availability of funds and progress achieved.
Research grant applications may be submitted by both
nonprofit and profit-making organizations and institutions,
state and local governments and their agencies, and eligible
agencies of the Federal government.
APPLICATION AND REVIEW PROCEDURES
The Division of Research Grants, NIH, serves as a central
point for receipt of applications for most discretionary PHS
grant programs. Applications in response to this
announcement will be assigned to an Initial Review Group
(IRG) in accordance with established PHS Referral
Guidelines. The IRGs, consisting primarily of non-federal
scientific and technical experts, will provide the peer
review for scientific merit of the proposed research,
potential significance of the research findings, adequacy of
methodology, availability of necessary facilities, and the
qualifications of the research team. A secondary review for
policy and program relevance to the research needs and
mission of the assigned Institute will be provided by its
Advisory Council.
Applications must be submitted using form PHS 398 (rev. 10/88),
"Application for Public Health Service Grant," available in
the business or grants office of most academic or research
institutions and from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health,
5333 Westbard Avenue, Westwood Building, Room 449, Bethesda, MD
20892. In order to
ensure proper identification of the application, line 2 of
the application form must state "Kidney Diseases Program
Announcement, PA-91-35" and check the "YES" box.
The first receipt date for applications will be June 1,
1991, that will receive IRG review in October-November 1991
and Advisory Council review in January-February 1992. The
earliest requested start date should be April 1, 1992.
Thereafter, the regular NIH receipt dates for grant
applications will pertain: October 1, February 1, and June
1 of each year.
The original and six copies of the application are to be
sent to:
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**
Applicants are encouraged to contact Dr. Scherbenske at the
address below prior to submitting applications:
M. James Scherbenske, Ph.D.
Renal Physiology/Cell Biology Program Director
DKUHD/NIDDK
Westwood Building, Room 621
Bethesda, MD 20892
Telephone: (301) 496-7458
FAX: (301) 496-9721
For fiscal and administrative matters, contact:
Linda Stecklein
Grants Management Specialist
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 639
Bethesda, MD 20892
Telephone: (301) 496-7467
This program is described in the Catalog of Federal Domestic
Assistance No. 93.849, Kidney, Urologic, and Hematologic Diseases
Research. Awards will be made under the authority of the Public
Health Service Act, Title III, Section 301 (Public Law 78-410, as
amended; 42 USC 241) and administered under PHS grant policies and
Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program
is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.
$$P1 END ***************************************************************
$$P2 BEGIN *************************************************************
SMALL GRANT PROGRAM
PA: PA-91-36
P.T. 34; K.W. 0715148, 0785055, 0755030, 0745027, 0745010, 0715020,
0710030
National Institute of Dental Research
Application Receipt Dates: December 3, April 3, August 3
PURPOSE
The Small Grant Program of the National Institute of Dental
Research (NIDR) provides awards of up to $50,000 each in direct
costs over a two-year period to support pilot projects conducted
by new and minority investigators, and other scientists, who
would benefit from assistance to position themselves to compete
successfully for research project grant support. The grants also
may be used to support high-risk venture research and other small
projects that do not lend themselves to support by the research
project grant mechanism.
OBJECTIVES AND ELIGIBILITY
The NIDR supports research on the causes, epidemiology,
prevention, diagnoses, and treatment of dental caries, periodontal
and soft tissue diseases, craniofacial anomalies, and orofacial
pain. This includes normal and abnormal craniofacial
development; the structure and function of the teeth, jaws, oral
mucosa, bone, connective tissue, salivary glands, and other organs
and tissues of the craniofacial complex; trigeminal neurobiology;
the relationship of behavioral, social, economic, and cultural
factors to oral diseases and conditions; dental biomaterials; and
the role of fluoride and nutrition in oral health and disease.
The NIDR emphasizes the need for research on older
Americans, minority groups, and individuals with medical and
handicapping conditions or who are otherwise at high risk for
oral health problems.
The primary objective of the NIDR Small Grant Program is to
provide career development opportunities for new and minority
investigators that will enable them to compete successfully for
research support as independent investigators. This
support may be research project grants (R01), FIRST awards (R29),
or grants from other governmental agencies, non-governmental
foundations or other organizations in the private sector.
Small Grants will permit recipients to obtain preliminary data
from which hypotheses can be developed, to test the feasibility of
an approach or experimental design, to gain experience with new or
unfamiliar methods, to initiate collaborative studies, and to
demonstrate research competence. These are important for
submitting competitive research project grant applications,
especially for first time applicants.
Because of the broadening scope of oral health research, this
award may be appropriate for experienced investigators planning
to explore new areas of research and for investigators working on
topics not included in traditional dental research.
Other objectives of the Small Grant Program are to encourage
venture research with high risk and possibly high pay-off;
support development of new techniques; support small clinical
projects; and address hypotheses by analysis of existing data.
The simplified application procedures, the reviewers' awareness
of the special objectives of this grant mechanism and the rapid
review and funding process work to the advantage of applicants.
SPECIAL TERMS OF THE AWARD
Applicants may request up to $50,000 in direct costs that may be
used for up to a 24-month period; however, no more than $35,000
may be awarded for any one year. The grant is not renewable;
however, grantees are encouraged to apply for a research project
grant or other support to maintain continuity in their studies.
The aims of the proposed project must be distinctly different
from those of pending grant applications or funded research
projects. The request may not be used to supplement currently
supported projects or to provide interim support for projects
under review by the Public Health Service.
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF
NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDY POPULATIONS
NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants will be required to include minorities and women
in study populations so that research findings can be of benefit
to all persons at risk of the disease, disorder or condition
under study; special emphasis should be placed on the need for
inclusion of minorities and women in studies of diseases,
disorders and conditions which disproportionately affect them.
This policy is intended to apply to males and females of all
ages. If women or minorities are excluded or inadequately
represented in clinical research, particularly in proposed
population-based studies, a clear compelling rationale should be
provided.
The composition of the proposed study group must be described in
terms of gender and racial/ethnic group. In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives
of the study. This information should be included in the form
PHS 398 in Section 2, A-D of the Research Plan and summarized in
Section 2, E, Human Subjects. Applicants are urged to assess
carefully the feasibility of including the broadest possible
representation of minority groups. However, the NIH recognizes
that it may not be feasible or appropriate in all research
projects to include representation of the full array of United
states racial/ethnic minority populations (i.e., Native
Americans, Asian/Pacific Islanders, Blacks, Hispanics).
The rationale for studies on single minority population groups
should be provided.
For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology,
prevention (and preventive strategies), diagnosis, or treatment
of diseases, disorders or conditions, including but not limited
to clinical trials.
The usual NIH policies concerning research on human subjects also
apply. Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.
However, every effort should be made to include human tissues
from women and racial/ethnic minorities when it is important to
apply the results of the study broadly, and this should be
addressed by applicants.
For foreign awards, the policy on inclusion of women applies
fully; since the definition of minority differs in other
countries, the applicant must discuss the relevance of the
research involving foreign population groups to the United
States' populations, including minorities.
If the required information is not contained in the application,
the application will be returned.
Peer reviewers will address specifically whether the research
plan in the application conforms to these policies. If the
representation of women or minorities in a study design is
inadequate to the scientific question(s) addressed and the
justification for the selected study population is inadequate, it
will be considered a scientific weakness or deficiency in the
study design and will be reflected in assigning the priority
score to the application.
All applications for clinical research submitted to NIH are
required to address these policies. NIH funding components will
not award grants or cooperative agreements that do not comply
with these policies.
REVIEW AND AWARD PROCEDURES
Applications will be reviewed for scientific merit by the NIDR
Special Grants Review Committee. Major factors to be considered
in the evaluation of an application include: its significance,
originality, feasibility and experimental design; the
qualifications of the investigator; the adequacy of the
facilities; the appropriateness of the budget; if clinical
studies are proposed, the availability and appropriateness of
study populations and the utilization of minorities and women as
study subjects; and the provisions for the protection of human
subjects and for the humane treatment of animals.
The extent to which applications meet the objectives of the Small
Grant Program, as outlined above, will be evaluated.
Applications will receive an expedited second level review and be
considered for funding on an accelerated schedule.
APPLICATION PROCEDURES
Investigators are urged to communicate with NIDR staff when
planning to submit an application. Advice and suggestions by
staff may materially assist applicants to ensure that the
objectives and format are acceptable.
APPLICATION REVIEW COMMITTEE SECONDARY EARLIEST POSSIBLE
RECEIPT DATE MEETING REVIEW BEGIN DATE
December 3 Feb/March May/June July 1
April 3 June/July Oct/Nov December 1
August 3 Oct/Nov Jan/Feb March 1
Applications must be prepared on form PHS 398 (rev. 10/88) and
is available at most institutional business offices and from the
Office of Grants Inquiries, Division of Research Grants,
Westwood Building, Room 449, Bethesda, MD 20892, telephone
(301) 496-7441.
To identify the application as a response to this Program
Announcement, check "YES" on Item 2 of page 1 of the application
and enter the PA number and the title "Small Grant
Program."
The instructions accompanying form PHS 398 must be followed as
far as possible but some modifications will be necessary. The
entire application may not exceed 25 pages and no appendix may be
submitted. Do not include reprints or manuscripts. Applications
not conforming with this instruction will be returned to the
applicant without review.
On page 1, item 6 - the maximum project period is two years; item
8 - the maximum direct costs is $50,000 and the total costs
include direct plus indirect costs.
Page Four - No more than $35,000 may be requested for any one
year, with a maximum direct cost of $50,000 for the two-year
project period. The budget should be limited to the following
categories: personnel, small equipment, supplies, and travel.
Requests for other expenditures, for the salary of the Principal
Investigator, or equipment over $1,000, will be honored only in
unusual circumstances; they should be specifically justified.
The original and four copies of the application must be sent
to:
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**
At the time of submission two copies of the application must also
be sent to:
Scientific Review Branch
National Institute of Dental Research
Westwood Building, Room 519
Bethesda, MD 20892-4500
Requests for additional information must be addressed to:
Director, Extramural Program
National Institute of Dental Research
Westwood Building, Room 503
Bethesda, MD 20892-4500
Telephone: (301) 496-7723
This program is described in the Catalog of Federal Domestic
Assistance No. 93.122.
Awards will be made under the authority of the Public Health
Service Act, Title III, Section 301 (Public Law 78-410, as
amended; 42 USC 241) and administered under PHS grant policies
and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This
program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency
review.
$$P2 END ***************************************************************
ERRATA
$$E1 BEGIN ES-91-02 ****************************************************
CORRECTION: SUPERFUND HAZARDOUS SUBSTANCES BASIC RESEARCH PROGRAM
RFA: ES-91-02
P.T. 34; K.W. 1007003, 1007009, 1002016, 0760003, 0755020, 0710030
National Institute of Environmental Health Sciences
This Request for Applications was published in the NIH Guide for
Grants and Contracts on March 15, 1991, Vol. 20, No. 11, and contained
an error in the MECHANISM OF SUPPORT section. The anticipated number
of awards was incorrectly stated at 40; the corrected sentence should
read: "It is anticipated that approximately 6-13 awards will be made
contingent upon the availability of funds."
$$E1 END ***************************************************************
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS
THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.
APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE
ADDRESS FOR THE WESTWOOD BUILDING IS:
5333 Westbard Avenue
Bethesda, Maryland 20816
FULL TEXT OF RFAs FOR ONLINE ACCESS